Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Oct 8;34(4):691. doi: 10.1016/j.ccell.2018.09.007. No abstract available.

2.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7. doi: 10.1016/j.ccell.2018.05.009. Erratum in: Cancer Cell. 2018 Oct 8;34(4):691.

3.

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T.

Adv Cancer Res. 2015;128:1-68. doi: 10.1016/bs.acr.2015.04.010. Epub 2015 Jun 9. Review.

PMID:
26216629
4.

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.

Schaer DA, Hirschhorn-Cymerman D, Wolchok JD.

J Immunother Cancer. 2014 Apr 15;2:7. doi: 10.1186/2051-1426-2-7. eCollection 2014. Review.

5.

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

Avogadri F, Zappasodi R, Yang A, Budhu S, Malandro N, Hirschhorn-Cymerman D, Tiwari S, Maughan MF, Olmsted R, Wolchok JD, Merghoub T.

Cancer Immunol Res. 2014 May;2(5):448-58. doi: 10.1158/2326-6066.CIR-13-0220. Epub 2014 Feb 26.

6.

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.

Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD.

Cancer Immunol Res. 2013 Oct;1(4):235-44. doi: 10.1158/2326-6066.CIR-13-0068.

7.

Agonist antibodies to TNFR molecules that costimulate T and NK cells.

Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD.

Clin Cancer Res. 2013 Mar 1;19(5):1044-53. doi: 10.1158/1078-0432.CCR-12-2065. Erratum in: Clin Cancer Res. 2013 Apr 1;19(7):1913.

8.

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.

Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD.

J Exp Med. 2012 Oct 22;209(11):2113-26. doi: 10.1084/jem.20120532. Epub 2012 Sep 24.

9.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

10.

Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.

Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD.

PLoS One. 2010 Sep 10;5(9). pii: e12670. doi: 10.1371/journal.pone.0012670.

11.

Cytokine-FC fusion genes as molecular adjuvants for DNA vaccines.

Hirschhorn-Cymerman D, Perales MA.

Methods Mol Biol. 2010;651:131-55. doi: 10.1007/978-1-60761-786-0_9.

PMID:
20686965
12.

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.

Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN.

Blood. 2010 Jun 3;115(22):4384-92. doi: 10.1182/blood-2009-11-251231. Epub 2010 Feb 12.

13.

The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, Rao U, Smith OM, King CG, Suh D, Hirschhorn-Cymerman D, Palomba L, Penack O, Holland AM, Jenq RR, Ghosh A, Tran H, Merghoub T, Liu C, Sempowski GD, Ventevogel M, Beauchemin N, van den Brink MR.

J Clin Invest. 2010 Jan;120(1):343-56. doi: 10.1172/JCI39395. Epub 2009 Dec 1.

14.

Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.

Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, Weinberg AD.

J Immunol. 2009 Oct 15;183(8):4853-7. doi: 10.4049/jimmunol.0901112. Epub 2009 Sep 28.

15.

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN.

J Exp Med. 2009 May 11;206(5):1103-16. doi: 10.1084/jem.20082205. Epub 2009 May 4.

16.

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN.

J Exp Med. 2009 Apr 13;206(4):849-66. doi: 10.1084/jem.20081382. Epub 2009 Mar 30.

17.

Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.

Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD.

Clin Cancer Res. 2006 Sep 15;12(18):5511-9.

18.

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR.

J Immunol. 2006 Jun 1;176(11):6434-42.

Supplemental Content

Loading ...
Support Center